Overcoming chemotherapy resistance
Our goal at Scandion Oncology is to develop drugs that specifically target chemotherapy resistance mechanisms. Improving the outcome and quality of life for cancer patients is our mission.
Drug resistance is one of the most significant challenges for successful medical treatment in oncology. Right now, half of all cancer patients fail chemotherapy.
Although many cancer patients initially benefit from chemotherapy, a large proportion develop resistance against chemotherapy drugs. Few of these patients survive.Read more about us
Scandion Oncology has two strong assets under clinical and pre-clinical development, in addition to over 800 analogues.
– Nils Brünner, CEO